Key Highlights
- Alnylam (NASDAQ:ALNY) fell 2.02% to USD 156.50 on November 17, 2026, about 4.9% above its 52-week low, with an RSI of 31.2.
- Third quarter net product Revenue rose 52% to USD 1.29 billion and Amvuttra sales rose 65% to USD 1.13 billion.
- The shares fell 25.1% on October 29, 2026 after management said it was not yet satisfied with underlying Demand growth.
- A USD 1 billion share buyback announced on November 4 has not stopped the decline, with the stock about 66% below its December 2025 high.
Strong Growth That Disappointed Expectations
Alnylam's third quarter growth would impress in most sectors. Total revenue rose 17% to USD 1.46 billion, and net product revenue jumped 52% to USD 1.29 billion. Amvuttra, its treatment for transthyretin amyloidosis with cardiomyopathy, generated USD 1.13 billion, up 65%, but that was roughly in line with or slightly below expectations, and part of the sequential increase came from inventory build and favourable pricing adjustments rather than patient demand. The chief executive said the company was not yet satisfied with underlying demand growth, and investors focused on that comment. Reported EPS was inflated by a non-cash tax benefit of about USD 1.9 billion, while adjusted Operating Income fell 11% as cost of goods and research spending rose. Full-year guidance for net product revenue of USD 4.7 billion to USD 5.1 billion was kept, but the TTR Franchise is tracking toward the low end of its USD 4.2 billion to USD 4.5 billion range. The shares of Alnylam (NASDAQ:ALNY) fell 25.1% on October 29, 2026.
Policy Headwinds and the Buyback
Two policy issues add uncertainty. A major Medicare Advantage insurer made its coverage policy for first-line Amvuttra more restrictive from October 1, and a proposed federal rule would substantially cut Medicare payment for drugs bought under the 340B discount program from January 1, 2027, if finalised. Management also flagged fourth quarter inventory and pricing headwinds. To support the shares, the board approved a USD 1 billion buyback after the close on November 4, when the stock stood at USD 161.08. The program equals about 5% of Market Value and uses less than 30% of the company's roughly USD 3.59 billion of cash and short-term investments. However, the stock closed at USD 151.64 on November 10, its lowest close in a year, and it remains well below the pre-announcement price. Over the past year the shares have given up about two-thirds of their value from a peak above USD 470. Cost pressures also matter: product gross Margin fell about five points to 72% and adjusted research spending rose 21%, so profit growth is lagging revenue growth.
Pipeline and Rebound Triggers
The longer-term story still has several catalysts. Nucresiran, a next-generation TTR silencer, is in Phase 3 trials, and zilebesiran for hypertension is in a Phase 3 outcomes study with a partner. A regulatory decision on a partnered myasthenia gravis drug that carries royalties is expected in November 2026, and new early data from obesity and other programs are due with full-year results in February 2027, when 2027 revenue guidance will also be given. Royalty revenue more than doubled in the quarter, and nine-month free Cash Flow was about USD 612 million. With an RSI of 31.2, the stock is close to oversold territory. A rebound would likely need evidence that new patient starts are accelerating and clarity on the 340B rule. Management has said it expects results at the lower end of the TTR range, so any fourth quarter prescription data that beat that lowered bar could shift sentiment quickly, particularly given how much of the earlier premium has already been removed.
Where Things Stand
Alnylam is still growing product revenue more than 50%, but slower Amvuttra demand growth and policy uncertainty have pushed the stock near its 52-week low despite a USD 1 billion buyback. New patient trends and February 2027 guidance are the key upcoming signals.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...